PAI
TCRT icon

Pittenger & Anderson Inc’s Alaunos Therapeutics TCRT Stock Holding History

Pittenger & Anderson Inc’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-5
Closed -$6K – 414
2015
Q4 		$6K Buy
+5
New +$8.27K ﹤0.01% 379

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BGA
Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Pittenger & Anderson Inc's TCRT Position: Q1 2016 in Review

Pittenger & Anderson Inc sold out of Alaunos Therapeutics (TCRT) in Q1 2016, closing a stake of 5 shares — an estimated $6K sold.

Pittenger & Anderson Inc first reported a position in TCRT in Q4 2015 and held it in 1 quarter. The position peaked at $6K in Q4 2015. 143 funds tracked by Wall St. Rank hold TCRT as of Q1 2016.

  • Pittenger & Anderson Inc reported no remaining Alaunos Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Pittenger & Anderson Inc sold 5 Alaunos Therapeutics shares in Q1 2016, an estimated $6K.
  • Pittenger & Anderson Inc first reported a position in Alaunos Therapeutics in Q4 2015 and held it in 1 quarter.
  • Pittenger & Anderson Inc's Alaunos Therapeutics position peaked at $6K in Q4 2015.
  • 143 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2016.

Based on Pittenger & Anderson Inc's 13F filing for Q1 2016, filed 13 May 2016.